H.R. 8205 — Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

What it does · Congressional Research Service

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

The “Reported to House” summary, Jul 9, 2026. Read it in full on congress.gov.

The record

Chamber: U.S. House
Status: Introduced — Introduced but not yet taken up. Most bills never advance.
Sponsor: Rep. Quigley, Mike [D-IL-5]
Introduced: Apr 6, 2026
Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466. (Jul 23, 2026)
Subjects: Health

Recorded floor votes

None yet.

More bills on these subjects

S.J.Res. 197 — A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program".
H.R. 4541 — To reauthorize the Young Women’s Breast Health Education and Awareness Requires Learning Young Act of 2009.
S. 5026 — Childhood Diabetes Reduction Act of 2026
S. 4974 — Making America's Food Safer Act
H.R. 9559 — IBOGAINE Act
H.R. 9544 — Save MEDICARE Act of 2026
S.J.Res. 198 — A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
S. 5012 — Welcome Back to the Health Care Workforce Act

Data via the ElectedConnect API. Official record.